Enhanced Recovery after Surgery and Endometrial Cancers: Results from an Initial Experience Focused on Elderly Patients

Author:

Miguet Céline1,Jauffret Camille1,Zemmour Christophe2,Boher Jean-Marie2ORCID,Sabiani Laura1ORCID,Houvenaeghel Gilles13,Blache Guillaume1,Brun Clément4,Lambaudie Eric13

Affiliation:

1. Department of Surgical Oncology, Institute Paoli-Calmettes, 13009 Marseille, France

2. Biostatistics and Methodology Unit, Department of Clinical Research and Investigation, Institute Paoli-Calmettes, Aix Marseille University, INSERM, IRD, SESSTIM, 13009 Marseille, France

3. Inserm, CNRS, Institute Paoli-Calmettes, CRCM, Aix Marseille University, 13009 Marseille, France

4. Department of Anaesthesiology, Institute Paoli-Calmettes, 13009 Marseille, France

Abstract

Endometrial cancer is the fifth most common cancer among French women and occurs most frequently in the over-70-year-old population. Recent years have seen a significant shift towards minimally invasive surgery and Enhanced Recovery After Surgery (ERAS) protocols in endometrial cancer management. However, the impact of ERAS on endometrial cancer has not been well-established. We conducted a prospective observational study in a comprehensive cancer center, comparing the outcomes between endometrial cancer patients who received care in an ERAS pathway (261) and those who did not (166) between 2006 and 2020. We performed univariate and multivariate analysis. Our primary objective was to evaluate the impact of ERAS on length of hospital stay (LOS), with the secondary objectives being the determination of the rates of early discharge, post-operative morbidity, and rehospitalization. We found that patients in the ERAS group had a significantly shorter length of stay, with an average of 3.18 days compared to 4.87 days for the non-ERAS group (estimated decrease −1.69, p < 0.0001). This effect was particularly pronounced among patients over 70 years old (estimated decrease −2.06, p < 0.0001). The patients in the ERAS group also had a higher chance of early discharge (47.5% vs. 14.5% in the non-ERAS group, p < 0.0001), for which there was not a significant increase in post-operative complications. Our study suggests that ERAS protocols are beneficial for the management of endometrial cancer, particularly for older patients, and could lead to the development of ambulatory pathways.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference30 articles.

1. (2022, September 27). Haute Autorite De Sante. Available online: https://www.has-sante.fr/upload/docs/application/pdf/2011-02/ald_30_gm_endometre_inca_has_web.pdf.

2. Endometrial Cancer;Lu;N. Engl. J. Med.,2020

3. (2022, October 04). Synthèse—Estimations Nationales de L’incidence et de la Mortalité par Cancer en France Métropolitaine Entre 1990 et 2018—Ref : SYNINCNAT2019. Available online: https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Synthese-Estimations-nationales-de-l-incidence-et-de-la-mortalite-par-cancer-en-France-metropolitaine-entre-1990-et-20182.

4. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up;Colombo;Ann. Oncol.,2016

5. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma;Concin;Int. J. Gynecol. Cancer,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3